aTyr Pharma (NASDAQ:LIFE) was downgraded by equities research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued on Wednesday, The Fly reports.
Several other brokerages have also weighed in on LIFE. Zacks Investment Research lowered shares of aTyr Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. ValuEngine lowered shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. aTyr Pharma currently has an average rating of “Hold” and a consensus price target of $4.81.
Shares of aTyr Pharma (LIFE) opened at $3.50 on Wednesday. The firm has a market cap of $101.18, a price-to-earnings ratio of -1.72 and a beta of 3.60. aTyr Pharma has a fifty-two week low of $2.30 and a fifty-two week high of $6.50. The company has a current ratio of 9.49, a quick ratio of 9.49 and a debt-to-equity ratio of 0.17.
Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP grew its holdings in aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 25,676 shares in the last quarter. Victory Capital Management Inc. acquired a new position in aTyr Pharma during the 3rd quarter worth $455,000. Renaissance Technologies LLC grew its holdings in aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after acquiring an additional 164,500 shares in the last quarter. Finally, Artal Group S.A. acquired a new position in aTyr Pharma during the 3rd quarter worth $1,263,000. 58.00% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/jpmorgan-chase-co-lowers-atyr-pharma-life-to-underweight.html.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.